ISSCR develops roadmap to accelerate pluripotent stem cell-derived therapies to patients
“Charting the Translational Pathway: ISSCR Best Practices for the Development of PSC-Derived Therapies,” offers insights into the comprehensive, globally informed guide to navigating the complex journey from laboratory discovery to approved therapy.
2026-01-22
(Press-News.org) The International Society for Stem Cell Research (ISSCR) today announced the upcoming release of “Charting the Translational Pathway: ISSCR Best Practices for the Development of Pluripotent Stem Cell (PSC)-Derived Therapies,” a new paper highlighting some of the most critical aspects of the ISSCR’s breakthrough interactive resource designed to transform how PSC-derived therapies are developed, evaluated, and advanced toward clinical and commercial success. The paper was published today in Stem Cell Reports.
As more than 100 PSC-derived products move through clinical trials worldwide, developers face a highly technical, expensive, and fragmented translational landscape. The ISSCR Best Practices addresses this challenge head-on by consolidating critical scientific, manufacturing, and regulatory guidance into a single, authoritative, openly accessible resource for academia, biotechnology, pharmaceutical companies, and manufacturers.
“A defining strength of the ISSCR is the capacity to convene cross-sector, international expertise to address shared challenges and develop field-shaping guidance,” said Keith Alm, chief executive officer of the ISSCR. “The Best Practices for the Development of PSC-Derived Therapies exemplifies this commitment and reflects the extraordinary leadership of its authors and the dedication of hundreds of volunteers who contributed their time and expertise. This resource serves as a tool for navigating the uncharted, a benchmark for rigor, and a catalyst for safe, effective cell therapies for patients.”
Developed by an international steering committee of leading cell therapy experts with extensive regulatory and community experience, the Best Practices document charts the full translational pathway across seven essential areas. The paper shares insights that emphasize the importance of choosing appropriate PSC starting material, meeting regulatory requirements across jurisdictions, and ensuring quality at every stage – from cell banking and ancillary materials to regulatory considerations and drug product manufacturing.
“Focused research drives discovery, but without clear translational guidance, even the most promising therapies can stall before reaching patients,” said Jacqueline Barry, co-chair of the ISSCR Best Practices Steering Committee and one of the paper’s authors. “The Best Practices document transforms decades of collective, global experience into actionable steps. Our paper seeks to call out the key elements of the complex resource and share how we hope stem cell scientists will learn from the experience of our community.”
The Best Practices document emphasizes a risk-based, end-to-end development strategy – starting with informed choices about PSC starting material and scaling through manufacturing, quality control, and regulatory engagement. Presented in an intuitive, visual, and interactive format, it is designed to support informed decision-making at every stage of development and will be updated regularly to reflect the rapidly evolving scientific and regulatory environment.
“This is a much-needed translational playbook for the field as evidenced by the response – more than 1,400 downloads from around the world in just a couple of months,” said Kapil Bharti, one of the paper’s co-authors and co-chair of the Best Practices Steering Committee. “In the paper, we distill some of the principles and practices that were derived over nearly two years of work by a global task force that collectively has decades of experience in developing cell therapy products. By clarifying key decision points and regulatory expectations early, we can increase both the speed and rigor of development and, most importantly, the number and quality of stem cell-based therapies that ultimately reach patients worldwide.”
“Charting the Translational Pathway: ISSCR Best Practices for the Development of PSC-Derived Therapies” underscores the ISSCR’s ongoing commitment to advancing responsible, evidence-based stem cell science and ensuring that groundbreaking discoveries translate efficiently into real-world medical impact. The full Best Practices document is available free, and the ISSCR welcomes continued feedback from the global community as the resource evolves.
About Stem Cell Reports
Stem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. Stem Cell Reports is a Cell Press partner journal. Find the journal on X: @StemCellReports.
About ISSCR
Across more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to advancing stem cell research and its translation to medicine.
###
END
ELSE PRESS RELEASES FROM THIS DATE:
2026-01-22
A new study led by Hartmut Geiger at the University of Ulm, Germany, and Yi Zheng and Kodandaramireddy Nalapareddy, Cincinnati Children's Hospital Medical Center (CCHMC), USA reveals that age-related changes in the gut microbiota directly impair intestinal stem cell (ISC) function and that restoring a youthful microbial environment can reverse this decline. The results were published today in Stem Cell Reports.
Cells lining the intestine are constantly renewed to maintain tissue integrity, nutrient absorption, and regenerative capacity following injury. This process ...
2026-01-22
About The Study: Mortality has decreased for every leading cancer-related death in people younger than 50 years in the U.S. except colorectal cancer, which is now the leading cancer death in females and males combined, up from the fifth-leading cancer death in the early 1990s. Breast cancer and leukemia mortality decreased despite increasing incidence.
Authors: Corresponding Author Rebecca Siegel, MPH, is available for interviews 11 AM-5 PM EST Tuesday, January 20. Senior Author Ahmedin Jemal, DVM, PhD, is ...
2026-01-22
About The Study: Rural hospital bypass (when rural residents receive care at hospitals other than their nearest hospital) rates among commercially insured patients were substantial between 2012 and 2021, generating large payments to receiving hospitals. Relative to Medicare bypass rates, commercial bypass rates were high in this sample. The findings of this study support concerns that commercial bypass contributes to financial distress at rural hospitals.
Corresponding Author: To contact the corresponding author, Caitlin E. Carroll, PhD, email carrollc@umn.edu.
To ...
2026-01-22
Scientists studying the fossil remains of giant prehistoric kangaroos have found that even animals weighing more than 200kg may not have been too big to bounce, overturning long-held assumptions about the limits of hopping.
Today, the red kangaroo is the largest living hopping animal and weighs around 90kg. But during the Ice Age, some kangaroos grew more than twice the size of that - some reaching up to 250kg.
For years, researchers believed these giants must have abandoned hopping, as earlier studies suggested that hopping would become mechanically ...
2026-01-22
For more than a decade, hospitals have worked to help older adults avoid repeated inpatient stays, incentivized by a federal program that cuts Medicare reimbursements if hospitals have higher-than-expected rates of readmissions for people with certain conditions.
The Hospital Readmissions Reduction Program has helped spur innovation, including initiatives to better prepare patients and their families to manage care after hospitalization, and to support them virtually at home.
But a new University of Michigan study finds that these financial penalties have hit some hospitals harder than they should, even if those hospitals have done a reasonable job at keeping people with heart ...
2026-01-22
[New York, NY [January 22, 2026]—Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells directly, it targets the cells that protect them.
The study, published in the January 22 online issue of Cancer Cell, a Cell Press Journal [DOI 10.1016/j.ccell.2025.12.021], was conducted in aggressive preclinical models of metastatic ovarian and lung cancer. It points to a new strategy ...
2026-01-22
A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer, according to a preclinical study by Weill Cornell Medicine investigators. The findings point to new possibilities for diagnosis, monitoring and treatment.
The study began with a focus on TL1A, an inflammatory immune signaling protein known to be associated with IBD and colorectal cancer. Experimental drugs that block TL1A activity have shown great promise against IBD in clinical trials, but how the signaling ...
2026-01-22
Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases. However, the field faces significant challenges, including a lack of standardized assessment methods, definitions, and diagnostic criteria, as well as an incomplete understanding of its pathophysiological mechanisms. This narrative review aims to synthesize current knowledge on myosteatosis in liver disease, covering its assessment, clinical impact across various etiologies, proposed ...
2026-01-22
The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases. To assist clinicians in rapidly mastering and standardizing the clinical application of FMT for chronic liver disease, the Liver-Related Digestive Diseases Group of the Chinese Society of Hepatology, Chinese Medical Association, has developed this expert consensus. The consensus comprehensively addresses key aspects of FMT application, including indications, contraindications, efficacy, safety, donor selection ...
2026-01-22
Presentations include first-in-human Phase 1 results in healthy volunteers, 13-week repeat-dose toxicology in two species, and disease mitigation in a chronic T cell transfer-induced colitis model
CAMBRIDGE, Mass. and SHANGHAI — January 22, 2026 — Insilico Medicine (“Insilico”, HKEX: 03696), a clinical-stage AI-driven biotechnology company, today announced it will present three abstracts at the 2026 Crohn’s & Colitis Congress 2026 in Las Vegas, USA on January 23, 2026 featuring new data supporting the continued development of ISM5411 (also referenced as ISM012-042), an orally administered, gut-restricted small-molecule ...
LAST 30 PRESS RELEASES:
[Press-News.org] ISSCR develops roadmap to accelerate pluripotent stem cell-derived therapies to patients
“Charting the Translational Pathway: ISSCR Best Practices for the Development of PSC-Derived Therapies,” offers insights into the comprehensive, globally informed guide to navigating the complex journey from laboratory discovery to approved therapy.
